Cytokinetics, Inc. : Cytokinetics to Present at 32nd Annual Canaccord Global Growth Conference

 Cytokinetics, Inc. : Cytokinetics to Present at 32nd Annual Canaccord Global
                              Growth Conference

South San Francisco, CA, August 9, 2013 - Cytokinetics, Incorporated (Nasdaq:
CYTK) announced today that Robert I. Blum, President and Chief Executive
Officer, is scheduled to present a corporate update at the 32^nd Annual
Canaccord Global Growth Conference on August 15, 2013 at 11:00 AM Eastern time
at the InterContinental Hotel in Boston, MA.

Interested parties  may  access the  live  audio  and slide  webcast  of  this 
presentation by visiting  the homepage  or Investor Relations  section of  the 
Cytokinetics website  at  www.cytokinetics.com.  The  webcast  replay  of  the 
presentation will be archived  on the Presentations  page within the  Investor 
Relations section  of  Cytokinetics'  website  for  two  weeks  following  the 
completion of the event.

About Cytokinetics

Cytokinetics is  a clinical-stage  biopharmaceutical  company focused  on  the 
discovery and development of novel  small molecule therapeutics that  modulate 
muscle function for the  potential treatment of  serious diseases and  medical 
conditions.  Cytokinetics'  lead  drug  candidate  from  its  cardiac   muscle 
contractility program, omecamtiv mecarbil, is in Phase II clinical development
for the potential treatment  of heart failure. Amgen  Inc. holds an  exclusive 
license worldwide to develop and commercialize omecamtiv mecarbil and  related 
compounds,   subject    to    Cytokinetics'    specified    development    and 
commercialization  participation   rights.   Cytokinetics   is   independently 
developing tirasemtiv,  a  fast  skeletal muscle  activator,  as  a  potential 
treatment for diseases  and medical conditions  associated with  neuromuscular 
dysfunction. Tirasemtiv is currently the subject of a Phase II clinical trials
program and has been granted orphan drug designation and fast track status  by 
the U.S. Food and Drug Administration and orphan medicinal product designation
by the European Medicines  Agency for the  potential treatment of  amyotrophic 
lateral  sclerosis,  a  debilitating  disease  of  neuromuscular   impairment. 
Cytokinetics is collaborating with Astellas Pharma Inc. to develop CK-2127107,
a  skeletal  muscle  activator  structurally  distinct  from  tirasemtiv,  for 
non-neuromuscular indications. All of these  drug candidates have arisen  from 
Cytokinetics' muscle  biology focused  research  activities and  are  directed 
towards  the   cytoskeleton.  The   cytoskeleton  is   a  complex   biological 
infrastructure  that  plays  a  fundamental  role  within  every  human  cell. 
Additional   information    about   Cytokinetics    can   be    obtained    at 
www.cytokinetics.com.

This press release  contains forward-looking  statements for  purposes of  the 
Private Securities Litigation  Reform Act  of 1995  (the "Act").  Cytokinetics 
disclaims any intent or obligation to update these forward-looking statements,
and claims  the  protection  of  the Act's  safe  harbor  for  forward-looking 
statements. Examples  of such  statements  include, but  are not  limited  to, 
statements relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug candidates.  Such 
statements are based on management's current expectations, but actual  results 
may differ materially due to  various risks and uncertainties, including,  but 
not limited to, potential difficulties or delays in the development,  testing, 
regulatory approval  and  production  of  Cytokinetics'  drug  candidates  and 
potential drug candidates that could  slow or prevent clinical development  or 
product approval, including risks  that current and  past results of  clinical 
trials or preclinical studies may not be indicative of future clinical  trials 
results and that Cytokinetics' drug  candidates and potential drug  candidates 
may have unexpected adverse side  effects or inadequate therapeutic  efficacy. 
For  further  information   regarding  these  and   other  risks  related   to 
Cytokinetics' business, investors  should consult  Cytokinetics' filings  with 
the Securities and Exchange Commission.

Contacts:
Cytokinetics, Incorporated:                       
Joanna L. Goldstein   
Manager, Investor Relations & Corporate Communications
(650) 624-3000

------------------------------------------------------------------------------

This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of
the
information contained therein.

Source: Cytokinetics, Inc. via Thomson Reuters ONE
HUG#1722342